The popular edible mushroom Ganoderma lucidum(Reishi) has been widely used for the general promotion of health and longevity in Asian countries. The dried powder of Ganoderma lucidumwas popular as a cancer chemotherapy agent in ancient China. The authors recently demonstrated thatGanoderma luciduminhibits constitutively active transcription factors nuclear factor kappa B (NF-.B) and AP-1, which resulted in the inhibition of expression of urokinasetype plasminogen activator (uPA) and its receptor uPAR.Ganoderma lucidumalso suppressed cell adhesion and cell migration of highly invasive breast and prostate cancer cells, suggesting its potency to reduce tumor invasiveness. Thus, Ganoderma lucidumclearly demonstrates anticancer activity in experiments with cancer cells and has possible therapeutic potential as a dietary supplement for an alternative therapy for breast and prostate cancer. However, because of the availability of Ganoderma lucidum from different sources, it is advisable to test its biologic activity.
References
1.
1.Yun TK. Update from Asia: Asian studies on cancer chemoprevention. Ann N Y Acad Sci. 1999;889:157-192.
2.
2. Go VL, Wong DA, Resnick MS, Heber D. Evaluation of botanicals and dietary supplements therapy in cancer patients. J Nutr. 2001;131(1):179S-180S.
3.
3. Heber D, Blackburn GL, Go VL. Nutritional Oncology. New York, NY: Academic Press; 1999.
4.
4. Kim SS, Kim YS. Korean Mushrooms. Seoul: Yupoong; 1990:298-299.
5.
5. Shiao MS, Lee KR, Lin LJ, Wang CT. Natural products and biological activities of the Chinese medical fungus, Ganoderma lucidum. In: Ho CT, Osawa T, Huang MT, Rosen RT, eds. Food Phytochemicals for Cancer Prevention. II. Teas, Spices, and Herbs. Washington, DC: American Chemical Society; 1994:342-354.
6.
6. Miyazaki T, Nishijima M. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem Pharmacol Bull. 1981;29(12):3611-3616.
7.
7. Sone Y, Okuda R, Wada N, Kishida E, Misaki A. Structure and antitumor activities of polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganoderma lucidum. Agric Biol Chem. 1985;49:2641-2653.
8.
8. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. Beta-glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol. 1999;163(6):3045-3052.
9.
9. Sasaki T, Arai Y, Ikekawa T, Chihara G, Fukuoka F. Antitumor polysaccharides from some polyporaceae, Ganoderma applanatum(Pers.) Pat and Phellinus linteus(Berk. et Curt) Aoshima. Chem Pharm Bull. (Tokyo)1971;19(4):821-826.
10.
10. Nakashima S, Umeda Y, Kanada T. Effect of polysaccharides from Ganoderma applanatumon immune response. I. Enhancing effect on the induction of delayed hypersensitivity in mice. Microbiol Immunol. 1979;23(6):501-513.
11.
11. Ukai S, Kiho T, Hara C, et al. Polysaccharides in fungi. XIII. Antitumor activity of various polysaccharides isolated from Dictyophora indusiata, Ganoderma japonicum, Cordyceps cicadae, Auricularia auricula-judae,and Auriculariaspecies. Chem Pharm Bull. (Tokyo)1983;31(2):741-744.
12.
12. Wang G, Zhang J, Mizuno T, et al. Antitumor active polysaccharides from the Chinese mushroom Songshan Lingzhi, the fruiting body of Ganoderma tsugae. Biosci Biotechnol Biochem. 1993;57(6):894-900.
13.
13. Zhang J, Wang G, Li H, et al. Antitumor active protein-containing glycans from the Chinese mushroom Songshan Lingzhi, Ganoderma tsugaemycelium. Biosci Biotechnol Biochem. 1994;58(7):1202-1205.
14.
14. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002;60(3),258-274.
15.
15. Wang SY, Hsu ML, Hsu HC, Lee SS, Shiao MS, Ho CK. The antitumor effect of Ganoderma lucidumis mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997;70(6):699-705.
16.
16. Hsu MJ, Lee SS, Lin WW. Polysaccharide purified from Ganoderma luciduminhibits spontaneous and Fas-mediated apoptosis in human neutrophils through activation of the phospatidylinositol 3 kinase/Akt pathways. J Leuokoc Biol. 2002;72(1):207-216.
17.
17. Hsu MJ, Lee SS, Lee ST, Lin WW. Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum. Brit J Pharmacol. 2003;139(2):289-298.
18.
18. Kim HS, Kacew S, Lee BM. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadendis Miller, Lentis edodes, Ganoderma lucidumand Coriolus versicolor). Carcinogenesis. 1999;20(8):1637-1640.
19.
19. Pincemail JJ. Free radicals and antioxidants in human diseases. In: Favier AE, Cadet J, Kalyanaraman B, Fontecave M, Pierre JL, eds. Analysis ofFr ee Radicals in Biological Systems. Berlin, Germany: Birkhauser Verlag; 1995:83-98.
20.
20. Lee JM, Kwon H, Jeong H, et al. Inhibition of lipid peroxidation and oxidative damage by Ganoderma lucidum. Phytother Res. 2001;15(3):245-249.
21.
21. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH. Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum(Reishi) polysaccharides: functional and proteomic analysis of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem. 2002;10(4):1057-1062.
22.
22. Zhang J, Tang Q, Zimmerman-Kordman M, Reutter W, Fan H. Activation of B lymphocytes by GLIS, a bioactive proteoglycan from Ganoderma lucidum. Life Sci. 2002;71(6):623-638.
23.
23. Mizushina Y, Hanashima L, Yamaguchi T, et al. A mushroom fruiting body-inducing substance inhibits activities of replicative DNA polymerases. Biochem Biophys Res Commun. 1998; 249(1):12-22.
24.
24. Shiao MS, Lee KR, Lin LJ, Wang CT. Natural products and biological activities of the Chinese medical fungus, Ganoderma lucidum. In: Ho CT, Osawa T, Huang MT, Rosen RT, eds. Food Phytochemicals for Cancer Prevention. II: Teas, Spices, and Herbs. Washington, DC: American Chemical Society; 1994: 342-354.
25.
25. Toth JO, Luu B, Ourission G. Les acides ganoderiques T & Z: triterpenes cytotoxiques de Ganodermalucidum (Polyporacee). Tetrahedron Lett. 1983;24(10):1081-1084.
26.
26. Lee S, Park S, Oh JW, Yang C. Natural inhibitors for protein prenyltransferase. Planta Medica. 1998;64(4):303-308.
27.
27. Min BS, Nakamura N, Miyashiro H,Bae KW, Hattori M. Triterpenes from the spores of Ganoderma lucidumand their activity against HIV-1protease. Chem Pharm Bull. 1998; 46(10):1607-1612.
28.
28. El-Mekkawy S, Meselhy MR, Nakamura N, et al. Anti-HIV-1and antiHIV-1-protease substances from Ganoderma lucidum. Phytochemistry. 1998;49(6):1651-1657.
29.
29. Min BS, Gao JJ, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidumand their cytotoxicity against Meth-A and LLC tumor cells. Chem Pharm Bull. 2000; 48(7):1026-1033.
30.
30. Kimura Y, Taniguchi M, Baba K. Antitumor and antimetastic effects on liver triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res. 2002;22(6A):3309-3318.
31.
31. Mau JL, Lin HC, Chen CC. Antioxidant properties of several medicinal mushrooms. J Agric Food Chem. 2002;50(21):6072-6077.
32.
32. Liu X, Yuan JP, Chung CK, Chen XJ. Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett. 2002;182(2):155-161.
33.
33. Wilasrusmee C, Kittur S, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes. J Altern Complement Med. 2002;8(4):467-475.
34.
34. Sliva D, English D, Lyons D, Lloyd FP Jr. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator (uPA) through the activation of AP-1and NF- .B. Biochem Biophys Res Commun. 2002; 290(1):552-557.
35.
35. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF- .B regulate motility of invasive MDA-MB-231human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem. 2002;277(5):3150-3157.
36.
36. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NWY. Ganoderma lucidumsuppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun. 2002;298(4):603-612b.
37.
37. Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidumextract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 2002;102(3):250-253.
38.
38. Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from Ganoderma luciduminhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci. 2003; 72(2):2381-2390.
39.
39. Cheung WMW, Hui WS, Chu PWK, Chiu SW, Ip NW. Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett. 2000;486(3):291-296.
40.
40. Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP Jr., Ho NWY. Biologic activity of Ganoderma lucidumfor the inhibition of highly invasive breast and prostate cancer cells. J Altern Complement Med. 2003;9(4):491-497.
41.
41. Hattori M. Recent studies on the bitter principles of Ganoderma lucidum—isolation of novel triterpenes, their biological activity and pharmacokinetics. Proceedings of the Int. Symposium Ganoderma Sci.; April 27-29, 2001; Auckland, New Zealand.
43. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Med. 1999;5(4):412-417.
44.
44. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001;20(22):2771-2780.
45.
45. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996;61(3):430-443.
46.
46. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev. 2001;21(2):146-170.
47.
47. Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mam Gland Biol. Neoplasia. 1999;4(2):153-164.
48.
48. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor .B activation: a major pathway of cell cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA. 2000;97(15):8542-8547.
49.
49. van Moorselaar RJA, Voest EE. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol. 2002;197(1-2):239-250.
